Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNB1344
- Development stage
- Discontinued
- Lead developer
- Synlogic
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SYNB1344 (SYN-MSUD) is an orally administered, non-pathogenic, engineered strain of *Escherichia coli* Nissle 1917 developed as a "Synthetic Biotic" for the treatment of Maple Syrup Urine Disease (MSUD). MSUD is a rare metabolic disorder characterized by the body's inability to process branched-chain amino acids (BCAAs), specifically leucine, isoleucine, and valine, leading to toxic accumulation. SYNB1344 is genetically modified to express a metabolic pathway that actively consumes these BCAAs within the gastrointestinal tract, thereby reducing their systemic levels and preventing neurological damage. Developed by Synlogic, the program aimed to provide a convenient alternative or adjunct to strict dietary protein restriction. However, development was halted following Synlogic's decision to cease operations and liquidate the company in early 2024.
Beyond the preview
Go deeper on SYNB1344.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNB1344.